Reprieve Cardiovascular touts early ADHF therapy study data

Reprieve Cardiovascular this week released early study results from the Target II study of its Reprieve-Guided Diuretic Therapy intended to improve fluid management for patients with acute decompensated heart failure, touting improvements in fluid management optimization.

Early data from the study were presented by study investigator Dr. Piotr Ponikowski of Wroclaw Medical University at the Heart Failure Congress this month, the Milford, Mass.-based company said.

“These results change the way we need to think about diuretic therapy. The new results of this study are encouraging as they show we were able to safely increase the rate of fluid loss in decompensated heart failure patients using Reprieve-Guided Diuretic Therapy,” Ponikowski said in a prepared statement.

Investigators in the study explored the use of Reprieve’s therapy to optimize fluid management for ADHF patients, looking to provide a safe net volume reduction and alleviate related symptoms, Reprieve Cardio said.

Results from the trial, which was based off the previously completed Target 1 feasibility trial, indicated that treatment with the therapy resulted in a net fluid loss off 3661 ml over 24 hours, significantly more than the 1754 ml reported in the control group from the Target 1 trial.

Reprieve Cardiovascular said it will release other details from the trial in the future.

“We are thrilled to reveal additional data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure. Reprieve Cardiovascular’s fluid management technology may precisely enable the controlled decongestive therapy that ADHF patients need. Our Guided Diuretic Therapy has the potential to establish a new frontline standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss. At D-HF we continued to see overwhelming interest in our initial study and technology, similar to the interest we experienced at the Heart Failure Society of America meeting in September and ESC – Heart Failure 2018 in May,” CEO Jim Dillon said in a press release.

In September, RenalGuard Solutions said that it closed a $7 million financing round joined by Abiomed (NSDQ:ABMD) to support its newly formed affiliate company, Reprieve Cardiovascular.

The post Reprieve Cardiovascular touts early ADHF therapy study data appeared first on MassDevice.

from MassDevice https://ift.tt/2ExwFsy